NO985293L - Nye 2,3-disubstituerte-4(3H)-kinazolinoner - Google Patents

Nye 2,3-disubstituerte-4(3H)-kinazolinoner

Info

Publication number
NO985293L
NO985293L NO985293A NO985293A NO985293L NO 985293 L NO985293 L NO 985293L NO 985293 A NO985293 A NO 985293A NO 985293 A NO985293 A NO 985293A NO 985293 L NO985293 L NO 985293L
Authority
NO
Norway
Prior art keywords
quinazolinones
disubstituted
new
Prior art date
Application number
NO985293A
Other languages
English (en)
Norwegian (no)
Other versions
NO985293D0 (no
Inventor
Mark L Elliott
Jr Willard M Welch
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO985293D0 publication Critical patent/NO985293D0/no
Publication of NO985293L publication Critical patent/NO985293L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)
NO985293A 1996-05-15 1998-11-13 Nye 2,3-disubstituerte-4(3H)-kinazolinoner NO985293L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1773896P 1996-05-15 1996-05-15
PCT/IB1997/000134 WO1997043276A1 (en) 1996-05-15 1997-02-17 Novel 2,3 disubstituted-4(3h)-quinazolinones

Publications (2)

Publication Number Publication Date
NO985293D0 NO985293D0 (no) 1998-11-13
NO985293L true NO985293L (no) 1999-01-13

Family

ID=21784266

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985293A NO985293L (no) 1996-05-15 1998-11-13 Nye 2,3-disubstituerte-4(3H)-kinazolinoner

Country Status (38)

Country Link
US (1) US6303615B1 (cs)
EP (1) EP0901487B9 (cs)
JP (1) JP3241388B2 (cs)
KR (1) KR100375155B1 (cs)
CN (2) CN1103772C (cs)
AP (1) AP1148A (cs)
AR (1) AR007118A1 (cs)
AT (1) ATE242232T1 (cs)
AU (1) AU730503B2 (cs)
BG (1) BG102999A (cs)
BR (1) BR9709085A (cs)
CA (1) CA2252907C (cs)
CZ (1) CZ295565B6 (cs)
DE (1) DE69722613T2 (cs)
DK (1) DK0901487T3 (cs)
DZ (1) DZ2237A1 (cs)
EA (1) EA002905B1 (cs)
ES (1) ES2198546T3 (cs)
GT (1) GT199700049A (cs)
HN (1) HN1997000052A (cs)
HR (1) HRP970261B1 (cs)
HU (1) HUP9902148A3 (cs)
ID (1) ID17149A (cs)
IL (1) IL126589A (cs)
IS (1) IS4881A (cs)
MA (1) MA26430A1 (cs)
NO (1) NO985293L (cs)
OA (1) OA10918A (cs)
PL (1) PL330042A1 (cs)
PT (1) PT901487E (cs)
SI (1) SI0901487T1 (cs)
SK (1) SK284108B6 (cs)
TN (1) TNSN97087A1 (cs)
TR (1) TR199802296T2 (cs)
TW (1) TW539675B (cs)
WO (1) WO1997043276A1 (cs)
YU (1) YU19197A (cs)
ZA (1) ZA974156B (cs)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1248254A (zh) 1997-02-28 2000-03-22 辉瑞产品公司 用于治疗神经变性疾病及与中枢神经系统创伤相关疾病的3－杂芳基－4(3h)－喹唑啉酮的阻转异构体
ID22711A (id) * 1997-02-28 1999-12-09 Pfizer Prod Inc Atropisomer dari 3-aril-4(3h)-kinazolinon dan penggunaannya sebagai antagonis reseptor-ampa
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
EP0900567A3 (en) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
ATE324369T1 (de) * 1999-02-15 2006-05-15 Eisai Co Ltd Heterodiazinon-derivate
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
PT1300396E (pt) 2000-06-12 2009-04-20 Eisai R&D Man Co Ltd Compostos de 1,2-di-hidropiridina, processos para a sua preparação e sua utilização
US7053216B2 (en) * 2001-11-19 2006-05-30 Iconix Pharmaceuticals, Inc. Modulators of Rho C activity
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
EP1480980A4 (en) 2002-02-15 2005-04-20 Cytokinetics Inc SYNTHESIS OF QUINAZOLINONES
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
KR20050036911A (ko) 2002-05-09 2005-04-20 싸이토키네틱스, 인코포레이티드 화합물들, 방법 및 조성물
US7038048B2 (en) 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
US7041676B2 (en) 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004009036A2 (en) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
JP2006501306A (ja) 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2005061460A1 (en) 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
TWI409070B (zh) * 2005-11-04 2013-09-21 Hydra Biosciences Inc 用於調節ｔｒｐｖ３功能之化合物
JP2010505811A (ja) 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
MX347987B (es) * 2007-09-26 2017-05-22 Celgene Corp * Derivados de quinazolinona 6-,7-, u 8-sustituidos y composiciones que los comprenden y metodos para usar los mismos.
NZ586552A (en) 2008-01-30 2012-06-29 Shin Poong Pharmaceutical Co Ltd Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
EP2355828B1 (en) 2008-11-13 2018-05-30 Gilead Calistoga LLC Therapies for hematologic malignancies
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
JP2012524126A (ja) 2009-04-20 2012-10-11 ギリアド カリストガ リミテッド ライアビリティ カンパニー 固形腫瘍の治療方法
WO2011011550A1 (en) 2009-07-21 2011-01-27 Calistoga Pharmaceuticals Inc. Treatment of liver disorders with pi3k inhibitors
WO2013105985A1 (en) * 2011-02-28 2013-07-18 Philadelphia Health & Education Corporation Small molecule inhibitors of rad51 recombinase and methods thereof
SI2834241T1 (sl) 2012-03-05 2021-06-30 Gilead Calistoga Llc Polimorfne oblike (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilkinazolin-4(3H)-ONA
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
CA2934531C (en) 2013-12-20 2020-02-25 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
US12303499B2 (en) 2018-12-14 2025-05-20 Eisai R&D Management Co., Ltd. Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds
PL4096661T3 (pl) 2020-01-29 2025-09-01 Kamari Pharma Ltd. Związki i kompozycje do zastosowania w leczeniu zaburzeń skóry
CN113831335A (zh) * 2020-06-24 2021-12-24 北京大学 吡啶[2,3-d]并嘧啶-4-(3H)-酮类化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3748325A (en) 1970-04-06 1973-07-24 Karamchand Premchand Private Process for the preparation of quinazolinone derivatives
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
ATE148120T1 (de) 1993-05-06 1997-02-15 Novo Nordisk As (1,2,4-triazolo(4,3-a>chinoxalinverbindungen deren herstellung und verwendung
GB9400680D0 (en) 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
ID22711A (id) 1997-02-28 1999-12-09 Pfizer Prod Inc Atropisomer dari 3-aril-4(3h)-kinazolinon dan penggunaannya sebagai antagonis reseptor-ampa

Also Published As

Publication number Publication date
DK0901487T3 (da) 2003-08-25
NO985293D0 (no) 1998-11-13
SI0901487T1 (en) 2003-10-31
KR20000011054A (ko) 2000-02-25
WO1997043276A1 (en) 1997-11-20
HN1997000052A (es) 1997-06-26
IL126589A (en) 2003-06-24
TNSN97087A1 (fr) 2005-03-15
US6303615B1 (en) 2001-10-16
EA199800923A1 (ru) 1999-06-24
HRP970261A2 (en) 2000-12-31
AP9701003A0 (en) 1997-07-31
KR100375155B1 (ko) 2003-08-19
IL126589A0 (en) 1999-08-17
HK1019607A1 (en) 2000-02-18
BG102999A (bg) 1999-09-30
ATE242232T1 (de) 2003-06-15
PL330042A1 (en) 1999-04-26
AU730503B2 (en) 2001-03-08
HUP9902148A2 (hu) 2000-04-28
PT901487E (pt) 2003-08-29
EP0901487A1 (en) 1999-03-17
CZ295565B6 (cs) 2005-08-17
AU1554997A (en) 1997-12-05
HUP9902148A3 (en) 2002-11-28
SK284108B6 (sk) 2004-09-08
AR007118A1 (es) 1999-10-13
CN1420114A (zh) 2003-05-28
CZ352698A3 (cs) 1999-11-17
CN1103772C (zh) 2003-03-26
AP1148A (en) 2003-02-28
SK152098A3 (en) 2000-05-16
EP0901487B9 (en) 2004-09-29
DZ2237A1 (fr) 2002-12-03
ID17149A (id) 1997-12-04
GT199700049A (es) 1998-10-21
JPH11514663A (ja) 1999-12-14
CA2252907C (en) 2005-05-17
BR9709085A (pt) 1999-08-03
DE69722613T2 (de) 2004-05-13
TW539675B (en) 2003-07-01
TR199802296T2 (xx) 1999-02-22
CA2252907A1 (en) 1997-11-20
JP3241388B2 (ja) 2001-12-25
ES2198546T3 (es) 2004-02-01
EP0901487B1 (en) 2003-06-04
MA26430A1 (fr) 2004-12-20
OA10918A (en) 2001-10-25
YU19197A (sh) 1999-09-27
ZA974156B (en) 1998-11-16
IS4881A (is) 1998-10-27
HRP970261B1 (en) 2003-06-30
DE69722613D1 (de) 2003-07-10
EA002905B1 (ru) 2002-10-31
CN1218464A (zh) 1999-06-02

Similar Documents

Publication Publication Date Title
NO985293L (no) Nye 2,3-disubstituerte-4(3H)-kinazolinoner
MA23780A1 (fr) Quinazolinones 2, 8 disubstitues
IS4970A (is) Setnar 6,6-heteró-bísýklískar afleiður
NO970512D0 (no) Nye heteroaryl-oksazolidinoner
TR199600265A1 (tr) Kinazolin türevleri.
ID17259A (id) Fluorina mengandung turunan piperidina 1,4-disubtitusikan
NO970374L (no) Nye forbindelser
NO983356L (no) Nye 19-nor-pregnenderivater
NO20001938D0 (no) Nye aryloksy-alkyl-dialkylaminer
DK0771789T3 (da) 1 alpha, 26-dihydroxy-D-homo-vitamin D3
DE69618634D1 (de) 1,4-benzodioxin-derivate
DK0906288T3 (da) Nye forbindelser
DE59507222D1 (de) Substituierte 1,2,3,4-tetrahydro-5-nitro-pyrimidine
NO985335D0 (no) 2,4-Diaminopyrimidinderivater
BR9609884A (pt) N-aril- 1,2,4-triazolin-5-onas
DE59607332D1 (de) Antineurodegenerativ wirksame 10-Aminoaliphatyl-dibenz- b,f oxepine
EP0811014A4 (en) Novel bacteriocin piscicolin 126
FI944655A7 (fi) Uudet 2,3-dihydro-2,2,4,6,7-penta-alkyyli-5-bentsofuranolit
NO990072D0 (no) Nye forbindelser
NO991097D0 (no) Nye fremgangsmÕter
NO973624L (no) Vasokonstriktive substituerte 2,3-dihydro-1,4-dioksinopiperidiner
NO983505D0 (no) Nye fenantrider